Low-cost generic drug programs have large gaps in coverage for core evidence-based CVD medications

A cross-sectional study of 19 low-cost generic programs (LCGPs) found that their medication coverage for six cardiovascular diseases (CVD) varied significantly between programs. Of all analyzed programs, Mark Cuban Cost Plus Drug Company demonstrated the most comprehensive coverage for all diseases included in the study. The findings are published in Annals of Internal Medicine.

Prescription Drug Spending per Covered Member Grew Much Faster in Individual Health Plans than Large Group Plans

Prescription drug spending per member covered—both before and after manufacturer rebates—grew much faster for those enrolled in individual health insurance plans compared to those enrolled in large group plans, according to new research.